Premium
Evaluation of a peptide‐based enzyme immunoassay for anti‐SARS coronavirus IgG antibody
Author(s) -
Chan Paul K.S.,
To W.K.,
Liu Esther Y.M.,
Ng T.K.,
Tam John S.,
Sung Joseph J.Y.,
Lacroix JeanMichel,
Houde Michel
Publication year - 2004
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.20207
Subject(s) - immunoassay , antibody , virology , enzyme , covid-19 , peptide , coronavirus , virus , severe acute respiratory syndrome coronavirus , immunoglobulin g , microbiology and biotechnology , chemistry , biology , medicine , immunology , biochemistry , disease , pathology , infectious disease (medical specialty)
High throughput assays for anti‐SARS‐CoV IgG antibody detection are need for large‐scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT‐SARS™, was evaluated for the detection of anti‐SARS‐CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high‐throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required. J. Med. Virol. 74:517–520, 2004. © 2004 Wiley‐Liss, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom